PTC Tumbles On Ataluren Failure In Cystic Fibrosis
Executive Summary
With a second Phase III failure in nonsense mutation CF, the New Jersey biotech ends development of ataluren for CF, but continues with the drug in three smaller indications.
You may also be interested in...
Lost $700m Opportunity As PTC Bids Farewell to Translarna in CF
In withdrawing its European marketing application for Translarna in cystic fibrosis, PTC Therapeutics has bid farewell to a market opportunity once pegged at $700m.
PTC Gambles On Success With Emflaza; Says Price Revision Is Needed
Looking to become a therapeutic area leader in DMD, PTC pays $140m up front for Marathon's controversial Emflaza, but the biotech's stock price plummeted, indicating that investors don't share PTC's optimism.
Keeping Track: Xermelo, Odactra, Noctiva Approved; Second Submissions For Avelumab And Deutetrabenazine
The latest drug development news and highlights from our US FDA Performance Tracker.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports